Table A3.
Clinical and Pathologic Features of the Patients in the Validation Case-Control Study Using Fresh-Frozen Tissues
| Variable | Cases (n = 21)
|
Controls (n = 35)
|
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age at surgery | .7603 | ||||
| Mean | 64.5 | 64.1 | |||
| Standard deviation | 8.9 | 8.3 | |||
| Median | 66.0 | 65.0 | |||
| Range | 48.0-77.0 | 48.0-76.0 | |||
| Preoperative PSA, ng/mL | .5765 | ||||
| Median | 12.8 | 10.8 | |||
| Q1 | 9.1 | 6.6 | |||
| Q3 | 18.0 | 24.9 | |||
| Range | 2.5-72.1 | 3.4-81.4 | |||
| Gleason score | .6389 | ||||
| 7 | 11 | 52.4 | 16 | 45.7 | |
| 8+ | 10 | 47.6 | 19 | 54.3 | |
| Pathologic stage, 1997 TNM | .8708 | ||||
| T2aN0 | 1 | 4.8 | 1 | 2.9 | |
| T2bN0 | 4 | 19.0 | 4 | 11.4 | |
| T3aN0 | 6 | 28.6 | 11 | 31.4 | |
| T3b4N0 | 7 | 33.3 | 11 | 31.4 | |
| TxN+ | 3 | 14.3 | 8 | 22.9 | |
| Margin positive | 14 | 66.7 | 15 | 42.9 | .0843 |
| Ploidy | .0167 | ||||
| Missing | 1 | 1 | |||
| Diploid | 9 | 45.0 | 10 | 29.4 | |
| Tetraploid | 8 | 40.0 | 24 | 70.6 | |
| Aneuploid | 3 | 15.0 | 0 | 0 | |
| Adjuvant treatment, < 90 days | |||||
| Hormone | 9 | 42.9 | 18 | 51.4 | .5343 |
| Radiation | 4 | 19.0 | 2 | 5.7 | .1183 |
Abbreviations: PSA, prostate-specific antigen; Q1, 25th percentile; Q3, 75th percentile.